The 2nd International Conference on Drug Discovery & Therapy: Dubai, February 1 - 4, 2010



The Regulatory Affairs track will provide an insight into the latest trends and cutting edge technology in drug development from both the pharmaceutical/biotech industry and regulatory authority perspectives. It is anticipated that the presentations from the major regulatory agencies (FDA, EMEA, HC etc) and some of the GCC countries will cover the regulatory aspects of drug development and drug life cycle, generic drugs and pharmacovigilance and risk management strategies. Delegates will be given the opportunity to gain insight from presenters with substantial collective, regulatory and pharmaceutical industry experience and expertise.


Abdullah M. Hassen
Medicines and Medical Products Health Authority
Abu Dhabi, UAE




Dr. Hassen obtained a B.Sc (Combined Honors) in Pharmacology and Biochemistry from the University of Aston-in-Birmingham, UK, and an M.Sc. in Toxicology from the University of Birmingham, UK. He obtained his doctoral degree in Toxicology from the University of Manitoba, Canada. After completing a post-doctoral fellowship in the Faculty of Pharmacy at the University of Toronto he joined the Therapeutic Products Directorate at Health Canada, Ottawa, in 1996. In 2002, he was appointed Manager of the Division of Gastroenterology in the Bureau of Gastroenterology, Infection and Viral Diseases. In 2009, he left Health Canada to take up a position with the Health Authority-Abu Dhabi, as Manager of the Pharma/Medicines and Medical Products Department.



[Webmaster]   Copyright © 2010 2nd International Conference on Drug Design & Therapy